Searchable abstracts of presentations at key conferences in endocrinology

ea0035p847 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

TSH-secreting pituitary adenoma treated conservatively with cabergoline for more than 10 years

Mathiopoulou Monika , Bukowczan Jakub , Lois Konstantinos , Quinton Richard

Background: TSH secreting pituitary adenomas represent small proportion of functional pituitary tumours presenting as hyperthyroidism with elevated thyroid hormone levels and inappropriately normal or increased TSH concentration. They are ≥1 cm in size and quite aggressive with tendency to relapse following transphenoidal adenomectomy (TSA). Surgical resection remains gold standard in their definitive treatment while pharmacotherapy with long-acting somatostatin analogue...

ea0035p846 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Resolution of severely impaired cognitive function following medical treatment of cystic invasive giant prolactinoma

Bukowczan Jakub , Lois Konstantinos , Mathiopoulou Monika , Kelly Tom , Abouglila Kamal , Mitra Dipayan , James Robert Andrew

Introduction: Giant prolactinomas are rare pituitary tumours. They can present with visual field defect, intracranial pressure symptoms and even temporal lobe epilepsy. Impairment of higher cognitive functions has been reported postoperatively after trans-cranial surgery and following radiotherapy. Reversible cognitive disturbances have been previously reported in patients with surgically decompressed arachnoid cysts but not after medical treatment of giant prolactinoma. We pr...